Complement Inhibitors for Traumatic Brain Injury
Corresponding Organization : Australian Research Council
Other organizations : Medical University of South Carolina
Variable analysis
- C1-Inh (15.0 IU; Berinert®; CSL Behring GmbH, Marburg, Germany) or 0.9% saline solution administered intravenously (i.v.) by the tail vein 1 h after the CCI injury
- CR2-Crry (10 mg/kg) or phosphate-buffered saline (PBS) administered i.v. by the tail vein at 1 and 7 h post-CCI
- PMX205 (1 mg/kg, synthesized in-house) or 5% glucose vehicle solution administered by i.p. injection at twice-daily intervals, commencing 1 h post-TBI over a 10-day period
- Outcomes not explicitly mentioned
- Isoflurane anesthesia for i.v. injections
- Restraint for i.p. injections
- Doses and administration times based on available literature
- C1-Inh (15.0 IU; Berinert®; CSL Behring GmbH, Marburg, Germany)
- CR2-Crry (10 mg/kg)
- PMX205 (1 mg/kg, synthesized in-house)
- 0.9% saline solution
- Phosphate-buffered saline (PBS)
- 5% glucose vehicle solution
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!